Andrew Robert Branagan, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Waldenstrom Macroglobulinemia | 43 | 2024 | 1076 | 3.090 |
Why?
|
Myeloid Differentiation Factor 88 | 8 | 2024 | 582 | 0.950 |
Why?
|
Adenine | 8 | 2024 | 995 | 0.890 |
Why?
|
Multiple Myeloma | 12 | 2024 | 5186 | 0.870 |
Why?
|
Influenza Vaccines | 2 | 2021 | 780 | 0.760 |
Why?
|
Paraproteinemias | 2 | 2021 | 251 | 0.710 |
Why?
|
Piperidines | 9 | 2024 | 1667 | 0.660 |
Why?
|
Influenza, Human | 2 | 2021 | 1543 | 0.580 |
Why?
|
Receptors, CXCR4 | 5 | 2021 | 729 | 0.550 |
Why?
|
Immunization, Secondary | 1 | 2017 | 373 | 0.460 |
Why?
|
Protein Kinase Inhibitors | 7 | 2024 | 5693 | 0.300 |
Why?
|
Lymphoma, B-Cell | 2 | 2022 | 945 | 0.250 |
Why?
|
Thalidomide | 3 | 2021 | 886 | 0.230 |
Why?
|
Mutation | 9 | 2024 | 30211 | 0.220 |
Why?
|
Pyrazoles | 5 | 2024 | 2028 | 0.210 |
Why?
|
Sulfonamides | 2 | 2024 | 1982 | 0.210 |
Why?
|
Antibodies, Monoclonal | 12 | 2020 | 9245 | 0.190 |
Why?
|
Pyrimidines | 5 | 2024 | 3044 | 0.190 |
Why?
|
Antineoplastic Agents | 10 | 2021 | 13650 | 0.180 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2022 | 631 | 0.170 |
Why?
|
SOXB1 Transcription Factors | 1 | 2021 | 283 | 0.160 |
Why?
|
Point Mutation | 2 | 2021 | 1591 | 0.160 |
Why?
|
Immunoglobulin M | 9 | 2009 | 1527 | 0.130 |
Why?
|
Glucosylceramides | 1 | 2016 | 27 | 0.130 |
Why?
|
Lysophosphatidylcholines | 1 | 2016 | 77 | 0.130 |
Why?
|
Neoplasm, Residual | 1 | 2021 | 1012 | 0.130 |
Why?
|
Consensus | 5 | 2023 | 3207 | 0.120 |
Why?
|
Blood Viscosity | 2 | 2006 | 125 | 0.120 |
Why?
|
Gaucher Disease | 1 | 2016 | 110 | 0.120 |
Why?
|
Hematologic Neoplasms | 2 | 2024 | 1907 | 0.120 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 9 | 2009 | 696 | 0.120 |
Why?
|
Plasma Cells | 2 | 2016 | 599 | 0.120 |
Why?
|
Humans | 59 | 2024 | 767040 | 0.120 |
Why?
|
Receptors, IgG | 3 | 2008 | 563 | 0.120 |
Why?
|
Lymphoma | 2 | 2022 | 1896 | 0.110 |
Why?
|
Immunoglobulins | 1 | 2016 | 853 | 0.100 |
Why?
|
Immunotherapy, Adoptive | 1 | 2022 | 1502 | 0.100 |
Why?
|
Antigens, CD | 4 | 2007 | 4032 | 0.100 |
Why?
|
Bone Marrow | 3 | 2021 | 2926 | 0.100 |
Why?
|
Mast Cells | 3 | 2008 | 1405 | 0.090 |
Why?
|
Aged | 19 | 2024 | 171319 | 0.090 |
Why?
|
Models, Animal | 1 | 2016 | 2121 | 0.090 |
Why?
|
Life Style | 1 | 2021 | 3931 | 0.080 |
Why?
|
Precancerous Conditions | 1 | 2016 | 980 | 0.080 |
Why?
|
Aged, 80 and over | 11 | 2024 | 59548 | 0.080 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2024 | 5332 | 0.080 |
Why?
|
Cyclophosphamide | 3 | 2023 | 2227 | 0.080 |
Why?
|
Antigens, CD20 | 2 | 2007 | 199 | 0.080 |
Why?
|
Bone Marrow Cells | 2 | 2006 | 2412 | 0.080 |
Why?
|
Prognosis | 7 | 2024 | 29963 | 0.080 |
Why?
|
Middle Aged | 20 | 2024 | 223233 | 0.080 |
Why?
|
Genomics | 2 | 2021 | 5924 | 0.070 |
Why?
|
Vidarabine | 1 | 2008 | 337 | 0.070 |
Why?
|
Tumor Microenvironment | 2 | 2019 | 3944 | 0.070 |
Why?
|
Double-Blind Method | 1 | 2021 | 12451 | 0.070 |
Why?
|
Hepatitis C Antibodies | 1 | 2007 | 151 | 0.070 |
Why?
|
Quality of Life | 3 | 2022 | 13485 | 0.060 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2021 | 8628 | 0.060 |
Why?
|
Neutropenia | 3 | 2022 | 892 | 0.060 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 5 | 2009 | 11872 | 0.060 |
Why?
|
Antibodies, Neoplasm | 1 | 2006 | 282 | 0.060 |
Why?
|
Exercise | 1 | 2021 | 5954 | 0.060 |
Why?
|
CD40 Ligand | 1 | 2006 | 528 | 0.060 |
Why?
|
Mastocytosis | 1 | 2006 | 150 | 0.060 |
Why?
|
Protease Inhibitors | 1 | 2007 | 750 | 0.060 |
Why?
|
DNA-Binding Proteins | 1 | 2021 | 9612 | 0.050 |
Why?
|
Pilot Projects | 1 | 2017 | 8732 | 0.050 |
Why?
|
Receptors, IgE | 1 | 2005 | 375 | 0.050 |
Why?
|
Adult | 14 | 2024 | 223317 | 0.050 |
Why?
|
Boronic Acids | 1 | 2007 | 915 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-hck | 1 | 2022 | 46 | 0.050 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2021 | 9410 | 0.050 |
Why?
|
Cell Proliferation | 2 | 2016 | 10455 | 0.050 |
Why?
|
Neprilysin | 1 | 2005 | 487 | 0.050 |
Why?
|
Anemia | 2 | 2009 | 1514 | 0.050 |
Why?
|
Genetic Linkage | 1 | 2007 | 2342 | 0.050 |
Why?
|
Pyrazines | 1 | 2007 | 1204 | 0.050 |
Why?
|
Male | 18 | 2024 | 364203 | 0.040 |
Why?
|
Retinal Vessels | 1 | 2006 | 863 | 0.040 |
Why?
|
Retinal Diseases | 1 | 2006 | 709 | 0.040 |
Why?
|
Vasodilator Agents | 1 | 2004 | 988 | 0.040 |
Why?
|
Female | 17 | 2024 | 396660 | 0.040 |
Why?
|
Hepacivirus | 1 | 2007 | 1342 | 0.040 |
Why?
|
src-Family Kinases | 1 | 2022 | 539 | 0.040 |
Why?
|
Survival Rate | 3 | 2021 | 12823 | 0.040 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2007 | 1372 | 0.040 |
Why?
|
Transplantation, Heterologous | 1 | 2007 | 2391 | 0.040 |
Why?
|
Gene Expression Profiling | 2 | 2005 | 9532 | 0.040 |
Why?
|
Prospective Studies | 5 | 2023 | 54886 | 0.040 |
Why?
|
Glycoproteins | 1 | 2006 | 2200 | 0.040 |
Why?
|
RNA, Viral | 1 | 2007 | 2867 | 0.040 |
Why?
|
Immunologic Factors | 1 | 2007 | 1592 | 0.040 |
Why?
|
Antigens, Neoplasm | 1 | 2006 | 1997 | 0.040 |
Why?
|
Polymorphism, Genetic | 2 | 2007 | 4247 | 0.040 |
Why?
|
Tumor Cells, Cultured | 2 | 2021 | 6106 | 0.040 |
Why?
|
MAP Kinase Signaling System | 1 | 2024 | 1492 | 0.040 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2021 | 3608 | 0.040 |
Why?
|
Pathology, Molecular | 1 | 2020 | 328 | 0.030 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2020 | 614 | 0.030 |
Why?
|
Hepatitis C | 1 | 2007 | 1594 | 0.030 |
Why?
|
Dexamethasone | 1 | 2023 | 1963 | 0.030 |
Why?
|
Mice | 4 | 2016 | 81912 | 0.030 |
Why?
|
Drug Administration Schedule | 3 | 2009 | 4855 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2021 | 1405 | 0.030 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2024 | 2058 | 0.030 |
Why?
|
Neoplasms | 1 | 2024 | 22350 | 0.030 |
Why?
|
Fatigue | 1 | 2022 | 1556 | 0.030 |
Why?
|
Cell Survival | 1 | 2024 | 5750 | 0.030 |
Why?
|
Practice Guidelines as Topic | 5 | 2020 | 7435 | 0.030 |
Why?
|
Follow-Up Studies | 4 | 2021 | 39317 | 0.030 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2024 | 2952 | 0.030 |
Why?
|
Piperazines | 1 | 2004 | 2548 | 0.030 |
Why?
|
Arrhythmias, Cardiac | 1 | 2024 | 2257 | 0.030 |
Why?
|
Nervous System Diseases | 1 | 2024 | 1660 | 0.030 |
Why?
|
Cell Line | 1 | 2007 | 15567 | 0.030 |
Why?
|
Disease Models, Animal | 2 | 2016 | 18330 | 0.030 |
Why?
|
Disease-Free Survival | 3 | 2008 | 6844 | 0.030 |
Why?
|
Neoplasm Transplantation | 1 | 2016 | 2012 | 0.030 |
Why?
|
DNA Mutational Analysis | 1 | 2021 | 4114 | 0.030 |
Why?
|
Mice, SCID | 2 | 2008 | 2626 | 0.030 |
Why?
|
Splenomegaly | 2 | 2003 | 191 | 0.030 |
Why?
|
Treatment Outcome | 7 | 2024 | 65295 | 0.020 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2022 | 2902 | 0.020 |
Why?
|
Lymphatic Diseases | 2 | 2003 | 318 | 0.020 |
Why?
|
DNA Copy Number Variations | 1 | 2020 | 2047 | 0.020 |
Why?
|
Cross-Sectional Studies | 2 | 2022 | 26325 | 0.020 |
Why?
|
Angiogenesis Inhibitors | 1 | 2021 | 2055 | 0.020 |
Why?
|
Thrombocytopenia | 2 | 2009 | 1172 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2023 | 3070 | 0.020 |
Why?
|
Mice, Transgenic | 2 | 2016 | 9551 | 0.020 |
Why?
|
Caregivers | 1 | 2022 | 2302 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 3804 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2021 | 3667 | 0.020 |
Why?
|
Disease Progression | 2 | 2021 | 13646 | 0.020 |
Why?
|
Time Factors | 3 | 2021 | 40154 | 0.020 |
Why?
|
Disease Management | 1 | 2019 | 2531 | 0.020 |
Why?
|
Recurrence | 3 | 2007 | 8504 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2024 | 17097 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2019 | 2824 | 0.020 |
Why?
|
Stress, Psychological | 1 | 2022 | 4526 | 0.020 |
Why?
|
Laser-Doppler Flowmetry | 1 | 2006 | 236 | 0.020 |
Why?
|
Ophthalmoscopy | 1 | 2006 | 172 | 0.020 |
Why?
|
Alkylating Agents | 1 | 2006 | 132 | 0.020 |
Why?
|
Interphase | 1 | 2005 | 226 | 0.020 |
Why?
|
Nucleosides | 1 | 2006 | 130 | 0.020 |
Why?
|
Flow Cytometry | 2 | 2005 | 5891 | 0.010 |
Why?
|
Karyotyping | 1 | 2005 | 1176 | 0.010 |
Why?
|
Bence Jones Protein | 1 | 2003 | 19 | 0.010 |
Why?
|
Vincristine | 1 | 2006 | 1040 | 0.010 |
Why?
|
GPI-Linked Proteins | 1 | 2005 | 472 | 0.010 |
Why?
|
Codon | 1 | 2005 | 599 | 0.010 |
Why?
|
Immunoglobulin G | 2 | 2007 | 4560 | 0.010 |
Why?
|
Immunotherapy | 1 | 2019 | 4745 | 0.010 |
Why?
|
Blood Flow Velocity | 1 | 2006 | 1374 | 0.010 |
Why?
|
Animals | 5 | 2016 | 168965 | 0.010 |
Why?
|
Cryoglobulinemia | 1 | 2003 | 84 | 0.010 |
Why?
|
Depression | 1 | 2022 | 8234 | 0.010 |
Why?
|
Plasmapheresis | 1 | 2003 | 205 | 0.010 |
Why?
|
Coculture Techniques | 1 | 2006 | 1337 | 0.010 |
Why?
|
beta 2-Microglobulin | 1 | 2003 | 330 | 0.010 |
Why?
|
Sulfones | 1 | 2004 | 447 | 0.010 |
Why?
|
Cells, Cultured | 2 | 2008 | 18989 | 0.010 |
Why?
|
Tumor Burden | 1 | 2008 | 1903 | 0.010 |
Why?
|
Splenectomy | 1 | 2003 | 390 | 0.010 |
Why?
|
Purines | 1 | 2004 | 614 | 0.010 |
Why?
|
Prednisone | 1 | 2006 | 1566 | 0.010 |
Why?
|
Neoplasms, Second Primary | 1 | 2008 | 1061 | 0.010 |
Why?
|
Clinical Trials as Topic | 2 | 2007 | 8048 | 0.010 |
Why?
|
Tomography, Emission-Computed | 1 | 2003 | 1007 | 0.010 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2005 | 2509 | 0.010 |
Why?
|
Immunoglobulin A | 1 | 2003 | 992 | 0.010 |
Why?
|
Salvage Therapy | 1 | 2006 | 1271 | 0.010 |
Why?
|
Doxorubicin | 1 | 2006 | 2229 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 4572 | 0.010 |
Why?
|
Myelodysplastic Syndromes | 1 | 2008 | 1399 | 0.010 |
Why?
|
Immunophenotyping | 1 | 2003 | 1864 | 0.010 |
Why?
|
Recombinant Fusion Proteins | 1 | 2006 | 3738 | 0.010 |
Why?
|
Remission Induction | 1 | 2003 | 2408 | 0.010 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2003 | 716 | 0.010 |
Why?
|
Pneumonia | 1 | 2008 | 2159 | 0.010 |
Why?
|
Hemoglobins | 1 | 2003 | 1531 | 0.010 |
Why?
|
Neoadjuvant Therapy | 1 | 2008 | 2902 | 0.010 |
Why?
|
Graft Survival | 1 | 2007 | 3896 | 0.010 |
Why?
|
Chromosome Aberrations | 1 | 2003 | 1776 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2008 | 10748 | 0.010 |
Why?
|
Protein Binding | 1 | 2008 | 9327 | 0.010 |
Why?
|
Amyloidosis | 1 | 2003 | 876 | 0.010 |
Why?
|
Stem Cell Transplantation | 1 | 2003 | 1596 | 0.010 |
Why?
|
Membrane Glycoproteins | 1 | 2005 | 3702 | 0.010 |
Why?
|
Retrospective Studies | 1 | 2022 | 81659 | 0.010 |
Why?
|
Glucocorticoids | 1 | 2003 | 2163 | 0.010 |
Why?
|
United States | 1 | 2021 | 72971 | 0.010 |
Why?
|
Cost of Illness | 1 | 2003 | 1951 | 0.010 |
Why?
|
Biopsy | 1 | 2005 | 6777 | 0.010 |
Why?
|
B-Lymphocytes | 1 | 2006 | 4787 | 0.010 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2008 | 3626 | 0.010 |
Why?
|
Genotype | 1 | 2007 | 13035 | 0.010 |
Why?
|
Weight Loss | 1 | 2003 | 2716 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2005 | 11063 | 0.010 |
Why?
|
Apoptosis | 1 | 2006 | 9513 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2008 | 22254 | 0.010 |
Why?
|
Incidence | 1 | 2005 | 21526 | 0.000 |
Why?
|
Age Factors | 1 | 2003 | 18401 | 0.000 |
Why?
|
Signal Transduction | 1 | 2006 | 23621 | 0.000 |
Why?
|
Tomography, X-Ray Computed | 1 | 2003 | 20741 | 0.000 |
Why?
|
Magnetic Resonance Imaging | 1 | 2003 | 36582 | 0.000 |
Why?
|